Zubsolv FDA Approval History
FDA Approved: Yes (First approved July 3, 2013)
Brand name: Zubsolv
Generic name: buprenorphine and naloxone
Dosage form: Sublingual Tablets
Company: Orexo AB
Treatment for: Opiate Dependence
Zubsolv (buprenorphine and naloxone) is a sublingual partial opioid agonist indicated for the maintenance treatment of opioid dependence.
Development Timeline for Zubsolv
|Oct 6, 2016||Approval FDA Approves Unique Low Dosage of Zubsolv|
|Aug 11, 2015||Approval FDA Approves Zubsolv for Induction of Buprenorphine Maintenance Therapy in Patients Suffering from Opioid Dependence|
|Dec 12, 2014||Approval FDA Approves Two Higher Dosage Strengths of Zubsolv|
|Jul 8, 2013||Approval FDA Approves Zubsolv for the Maintenance Treatment of Opioid Dependence|
|Nov 19, 2012||Orexo announces that Zubsolv has been accepted for review by the U.S. Food and Drug Administration (FDA)|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.